Cantor Fitzgerald analyst Steven Halper views the post-earnings selloff today in shares of Evolent Health as unwarranted. While the Q3 guidance was a bit below his estimate, the analyst believes Evolent’s confidence in its pipeline is increasing. This should allay investors’ concerns regarding the company’s current and long-term growth strategy, Halper tells investors in a research note. He reiterates an Overweight rating on the shares with a $28 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.